查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球无内胎胰岛素帮浦市场 - 2023-2030
市场调查报告书
商品编码
1374847

全球无内胎胰岛素帮浦市场 - 2023-2030

Global Tubeless Insulin Pumps Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

无管胰岛素帮浦基本上是作为贴片直接佩戴在身体上，并透过无线手持设备进行控制，从而实现谨慎的胰岛素输送。此帮浦没有萤幕，由触控萤幕手持装置透过蓝牙进行无线控制。它包括放置在防水闭环胰岛素帮浦中的演算法，并直接与连续血糖监测仪通讯以实现胰岛素释放过程。

此外，无管胰岛素帮浦可以帮助第1型和第2型糖尿病患者方便地管理血糖值。这些小型设备在特定时间内提供一定剂量的胰岛素。无管胰岛素帮浦是比胰岛素笔注射和其他胰岛素设备更灵活的选择。这些不一定是永久性的，可以随时切换到另一种胰岛素管理方法。无管胰岛素帮浦对患者有利，可以使用无线设备进行胰岛素输送。

市场动态：驱动因素

无管胰岛素帮浦不断进步

无内胎帮浦的不断进步预计将在预测期内推动市场发展。这些帮浦的进步预计将增加无管胰岛素帮浦的采用。无管胰岛素帮浦技术的进步可能会导致设备更小、更舒适、更容易使用。使用者体验的改善可以提高患者满意度。

例如，2023年8月，罗氏推出了Accu-Chek Solo胰岛素贴片帮浦和无线触控萤幕手持设备，并已获得FDA核准用于2岁及以上糖尿病患者。该系统包括一个无管胰岛素帮浦和一个带蓝牙的无线手持控制器，该控制器整合了血糖监测并提供推注建议。此胰岛素帮浦系统无管、体积小、重量轻。该装置是可拆卸的，允许糖尿病患者在必要时改变输注部位。

此外，如果无管胰岛素帮浦设计为与 CGM 系统无缝集成，从而实现更好的血糖监测和自动胰岛素调整，则可以显着增强糖尿病管理。这会带来更好的患者治疗结果，并进一步增加先进设备的采用。

例如，2023 年 6 月 20 日，全球无管胰岛素帮浦技术领导者 Insulet Corporation 及其 Omnipod 品牌产品推出了 Omnipod 5 自动胰岛素输送系统 (Omnipod 5)，适用于 2 岁及以上 1 型糖尿病患者在英国。 Omnipod 5 系统是简单性与先进技术的结合。 Omnipod 5 是首款获得 CE 标誌的无内胎混合闭环系统，与 Dexcom G6 连续血糖监测 (CGM) 系统集成，可自动调节胰岛素输送并帮助防止血糖水平过高或过低。

此外，无线连接和无管胰岛素帮浦智慧功能的结合可以让使用者透过数位平台监控和控制胰岛素输送。这种程度的连接可以提高患者的便利性。总体而言，无管胰岛素帮浦的进步提高了使用者的便利性并进一步提高了采用率。

例如，2023 年 2 月 14 日，EOFlow Co. 在阿联酋推出了无内胎、穿戴式、一次性胰岛素帮浦 EOPatch。在阿联酋，可以使用全新的 Narsha 应用程式直接透过 Android 和 iOS 智慧型手机透过 EOPatch 控制和管理胰岛素输注。

此外，糖尿病盛行率的增加、FDA 批准等监管部门的批准不断增加、人们对无管胰岛素帮浦优势的认识不断提高以及设备的技术进步预计将在预测期内推动市场发展。

限制

无管胰岛素帮浦相关的併发症和风险以及这些设备的高成本等因素预计将阻碍市场的发展。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按类型分類的片段
  • 按组件分類的片段
  • 按应用程式片段
  • 按配销通路分類的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 无内胎胰岛素帮浦不断进步
    • 限制
      • 设备成本高
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 管道分析
  • 未满足的需求
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按类型

  • 胰岛素贴片泵
  • 附一次性储液器的传统泵

第 8 章：按组件

  • 胰岛素帮浦（荚）
  • 遥控器

第 9 章：按应用

  • 1 型糖尿病
  • 2型糖尿病

第 10 章：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • Insulet Corporation
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • F. Hoffmann-La Roche Ltd
  • Debiotech SA
  • CeQur Corporation
  • Terumo Corporation
  • Tandem Diabetes Care, Inc.
  • EOFLOW CO., LTD.
  • Medtrum Technologies Inc.
  • Microtec Medical
  • Ascensia Diabetes Care Holdings AG

第 14 章：附录

简介目录
Product Code: MD7390

Overview

Tubeless insulin pumps are basically worn as a patch directly on the body and controlled from a wireless handheld device, enabling discreet insulin delivery. The pump does not have a screen and is controlled wirelessly from a touchscreen handheld via Bluetooth. It includes an algorithm placed in a waterproof, closed-loop insulin pump and communicates directly with a continuous glucose monitor for the insulin-releasing process.

Moreover, tubeless insulin pumps can help people with type-1 and type-2 diabetes conveniently to manage their blood sugar levels. These small devices deliver doses of insulin at specific times. The tubeless insulin pumps are a more flexible option than insulin pen injections and other insulin devices. These don't have to be permanent and can switch to another insulin management method at any time. Tubeless insulin pumps are favorable to the patients, insulin delivery can be done by using wireless devices.

Market Dynamics: Drivers

Increasing advancements in tubeless insulin pumps

The increasing advancements in tubeless pumps are expected to drive the market over the forecast period. The advancements in these pumps are expected to increase the adoption of tubeless insulin pumps. Advancements in tubeless insulin pump technology may result in devices that are smaller, more comfortable, and easier to use. Improvements in user experience can lead to increased patient satisfaction.

For instance, in August 2023, Roche launched its Accu-Chek Solo insulin patch pump and wireless touchscreen handheld device and it has received FDA approval for people with diabetes aged 2 years and older. The system includes a tubeless insulin pump and a wireless handheld controller with Bluetooth, which integrates with blood glucose monitoring and provides bolus advice. This insulin pump system is tubeless, small and lightweight. The device is detachable, allowing people with diabetes to change the infusion site when necessary.

Moreover, if tubeless insulin pumps are designed to integrate seamlessly with CGM systems, allowing for better glucose monitoring and automated insulin adjustments, it can significantly enhance diabetes management. This results in better patient outcomes and further this increases the adoption of advanced devices.

For instance, on June 20, 2023, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod brand of products, launched its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes in the United Kingdom. The Omnipod 5 System is where simplicity meets advanced technology. Omnipod 5 is the first CE-marked tubeless hybrid closed loop system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin delivery and help protect against high and low glucose levels.

Furthermore, the incorporation of wireless connectivity and smart features of tubeless insulin pumps can empower users to monitor and control their insulin delivery through digital platforms. This level of connectivity can improve patient convenience. Overall, the advancements in tubeless insulin pumps improve user convenience and further increase adoption.

For instance, on February 14, 2023, EOFlow Co. launched its tubeless, wearable, and disposable insulin pump EOPatch in the UAE. It becomes possible in the UAE to control and manage insulin infusions with EOPatch directly from Android and iOS smartphones using the brand-new Narsha app.

In addition, the increasing prevalence of diabetes, rising regulatory approvals such as FDA approvals, increasing awareness about the advantages of tubeless insulin pumps and technological advancements in the devices are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and risks associated with tubeless insulin pumps and the high cost of these devices are expected to hamper the market.

Segment Analysis

The global tubeless insulin pumps market is segmented based on type, component, application, distribution channel and region.

The insulin patch pumps segment accounted for approximately 43.2% of the tubeless insulin pumps market share

The insulin patch pumps segment is expected to hold the largest market share over the forecast period. Insulin patch pumps are a type of wearable insulin delivery device that adheres to the skin, typically in the form of a patch. These pumps are designed to provide a continuous delivery of insulin. They offer advantages such as discreetness, ease of use, and reduced interference with daily activities.

Moreover, insulin patch pumps are usually designed to adhere securely to the skin, allowing users to wear them for an extended period without discomfort. For instance, on November 16, 2022, Dexcom U.K. launched a campaign led by four local celebrities who designed their own continuous glucose monitor (CGM) insulin patch pumps to tell their Diabetes Story.

Due to the rising prevalence of diabetes, there is a continuously increasing demand for the use of tubeless insulin pumps. For instance, according to the Centers for Disease Control and Prevention, 2022, there are a total of 37.3 million people have diabetes. These insulin patch pumps are often compact and discreet, making them less noticeable and more convenient for users.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing advancements. North America especially the United States is home to the presence of major players such as medical device companies, which are primarily focussing on the development of tubeless insulin pumps by offering more advanced features to increase patient convenience.

For instance, on April 25, 2023, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod brand of products, released the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. With its tubeless and waterproof pod, the Omnipod GO provides an alternative to traditional insulin delivery methods.

Furthermore, increasing advancements for tubeless insulin pumps in the region are also expected to drive the market in the region. For instance, on August 11, 2022, EOFlow officially launched its tubeless, wearable, and disposable insulin pump under the diabetes care brand GlucoMen Day PUMP. These advancements increase the adoption of tubeless insulin pumps in the region.

Competitive Landscape

The major global players in the tubeless insulin pumps market include: Insulet Corporation, F. Hoffmann-La Roche Ltd, Debiotech SA, CeQur Corporation, Terumo Corporation, Tandem Diabetes Care, Inc., EOFLOW CO., LTD., Medtrum Technologies Inc., Microtec Medical and Ascensia Diabetes Care Holdings AG among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global tubeless insulin pumps market. During the pandemic, the demand for the tubeless insulin pumps has increased. For instance, according to NIH 2020, obesity and diabetes are two major risk factors for COVID-19 hospitalization. The organization stated that people with diabetes mellitus and severe obesity are more likely to get infected and are at a higher risk of mortality from COVID-19. Among elderly patients who are at higher risk of death from COVID-19, 26.8% have diabetes mellitus, this increased the demand for the adoption of tubeless insulin pumps. However, the pandemic also disrupted the supply chain of these devices globally.

Market Segmentation

By Type

  • Insulin Patch Pumps
  • Traditional Pumps with Disposable Reservoirs

By Component

  • Insulin Pump (Pod)
  • Remote Controller

By Application

  • Type-1 Diabetes
  • Type-2 Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global tubeless insulin pumps market segmentation based on type, component, application, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of tubeless insulin pumps market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global tubeless insulin pumps market report would provide approximately 69 tables, 64 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Component
  • 3.3. Snippet by Application
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Advancements in Tubeless Insulin Pumps
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Insulin Patch Pumps*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Traditional Pumps with Disposable Reservoirs

8. By Component

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 8.1.2. Market Attractiveness Index, By Component
  • 8.2. Insulin Pump (Pod)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Remote Controller

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Type-1 Diabetes*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Type-2 Diabetes

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Insulet Corporation*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. F. Hoffmann-La Roche Ltd
  • 13.3. Debiotech SA
  • 13.4. CeQur Corporation
  • 13.5. Terumo Corporation
  • 13.6. Tandem Diabetes Care, Inc.
  • 13.7. EOFLOW CO., LTD.
  • 13.8. Medtrum Technologies Inc.
  • 13.9. Microtec Medical
  • 13.10. Ascensia Diabetes Care Holdings AG

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us